A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. - Wikidata - wikimedia - TriplyDB

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

http://www.wikidata.org/entity/Q36821702

about

Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients Heat shock protein 90 targeting therapy: state of the art and future perspective Ganetespib: research and clinical development Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Cytoplasmic HSP90α expression is associated with perineural invasion in pancreatic cancer.Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.Re-examining HSPC1 inhibitors.Regulation of Apoptosis by HER2 in Breast Cancer.TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death.Targeting protein quality control pathways in breast cancer.Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70.

P2860

Q26752024-C6B0931E-9FC7-433F-8BCD-CF72085F2EB0 Q26776302-DD094980-7853-46C5-A029-EB4AB5E8D389 Q26798645-94B8B2F8-8987-4836-B421-F948D5430F84 Q28829301-38F07F8B-9D32-4B7E-B7D3-84B175D7124B Q30857631-79747C3A-ADAF-4CD4-A954-6124ABF15012 Q33898794-1E496596-D635-4834-A2AD-44B8412E19E9 Q34016480-1DFBBD36-C23D-4FCB-A78C-B768026C80FC Q34164027-C852AFA9-97F3-4663-AD80-C6788EAF5ED7 Q34268618-ABCD6851-33FC-4236-9986-B9C4CC4C02CD Q34677194-89BD1B42-44C8-4269-A1AF-E13D049E0CB0 Q37198085-1A30D0FF-4395-49D8-8095-FDB11F5A4287 Q37204596-92172164-6354-4B8C-A9BD-90E6003EC7FE Q38382840-8D5EB771-07D5-4816-8D7E-B6F9E59DC3EF Q38648408-41C00522-D7BE-4D88-9AFF-6319E531CA66 Q38740513-0BF48A2A-2568-483F-A60B-9B668E16B3E7 Q38906493-727210DF-5D28-4BD1-8B7A-12705B65D271 Q38931732-60B08EE2-B808-4406-AA96-43AAFDA0A270 Q39843650-516B5FA4-E33E-48FB-98E1-57980989AD5D Q42317467-3A0C58D5-A6C0-4366-B814-B82473BABA37 Q46087491-55D0B8B9-99BF-498C-A6F9-40A3968F5A59 Q48596233-1CDF0154-CFFB-4A52-A53D-478395A45637 Q52578959-C2C6D08E-11B9-4FF1-B56F-AC464575614E Q53663668-64E605F4-A963-4F5A-A88A-307E3EB911DE

P2860

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

http://www.wikidata.org/entity/Q36821702

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A multicenter trial evaluating ...... c HER2-positive breast cancer.

@en

type

label

A multicenter trial evaluating ...... c HER2-positive breast cancer.

@en

prefLabel

A multicenter trial evaluating ...... c HER2-positive breast cancer.

@en

P1433

Q36821702-AA7E4E13-D3BE-4EC0-96D9-0D2CF87414ED

P1476

Q36821702-6A9B4647-D570-4E0B-9596-17AFA705655C

P2093

Q36821702-0F52E4E0-30D3-434B-934A-AE0E558CC3AA

Q36821702-2F76FAA1-89E6-416F-8AB3-7F53BA360EFC

Q36821702-41800900-67FE-4568-A42F-9BC8D1E39566

Q36821702-4979994F-2A36-4E38-9E8B-BBC4B5102B04

Q36821702-6D93FF68-BD5F-483F-888E-D4A41BDC844F

Q36821702-A6284EE5-0878-4A6A-BA20-5AAD96B125F6

Q36821702-B5A1AFC7-1D46-4078-A150-369F80CA521B

Q36821702-FEB852BC-83F8-4000-82DE-FEC26F78EDAB

P2860

Q36821702-1F5AAC50-55DE-41BD-A121-6AE400FEF1B5

Q36821702-24D4DDE5-1664-46DE-81A0-04A8BD5903EA

Q36821702-3024A695-502E-40D1-8BB6-E8F762CEE1A1

Q36821702-46E64EDB-BA54-4850-ABF8-6CE9C37F6735

Q36821702-512FBF88-D083-413C-AB98-AB097BD0BC10

Q36821702-8809867F-6857-4624-A8BC-E196C142EEC4

Q36821702-A477C66B-F1FB-4E9C-BEAA-AECC4BDF3FCB

Q36821702-C62C50A9-6D93-4C51-8DAF-3F82E8A59AC4

Q36821702-D2851C60-8377-42D7-881F-5AE7641C8904

Q36821702-EA6E1396-328F-4A30-B69D-FB5F296692D3

P2888

Q36821702-541D07EA-C4E9-4E14-91D9-F9BAABBEBD2D

P304

Q36821702-4B940E71-C05D-4BA2-8816-089C0AC6ED12

P31

Q36821702-3ABBDAD6-C03A-4173-AA0C-92EA4C068493

P356

Q36821702-391F75B7-BFBC-4164-AE1B-AEDE5F77EEFA

P407

Q36821702-ACFC2D0B-16D5-4B6C-B400-A0769960E72C

P433

Q36821702-728B6B33-7C10-4621-946C-48390CDCD58A

P478

Q36821702-C9E6BB7C-26B9-4A35-9AE9-6625DE74A760

P50

Q36821702-7209064A-55E9-40DE-8321-853701767EDA

Q36821702-C149857A-1C85-43B0-83B3-981D0A724BD8

P577

Q36821702-D97D7DC2-32A4-481E-B9CF-EC8EFD3B5517

P5875

Q36821702-884EAF2C-ABF4-48E7-B242-6A5FC43D7EBF

P698

Q36821702-CC25942E-11CB-46DD-ACFF-1F2CD9D0FAAB

P921

Q36821702-CBA94CC9-0E91-498C-B74F-D704E10EB745

P932

Q36821702-D19D2EF8-4506-4885-9BBD-57B5C83222DC

P356

S10549-013-2510-5

P1433

Breast Cancer Research and Treatment

P1476

A multicenter trial evaluating ...... c HER2-positive breast cancer.

@en

P2093

Charles Henderson

http://www.w3.org/2001/XMLSchema#string

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

Cristina Saura

http://www.w3.org/2001/XMLSchema#string

Eduardo Rodenas

http://www.w3.org/2001/XMLSchema#string

Jill Goddard

http://www.w3.org/2001/XMLSchema#string

Joyce O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Nancy U Lin

http://www.w3.org/2001/XMLSchema#string

Reshma Mahtani

http://www.w3.org/2001/XMLSchema#string

P2860

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Geldanamycin selectively targets the nascent form of ERBB3 for degradation

Dose scheduling--Herceptin.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

P2888

s10549-013-2510-5

P304

107-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2510-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236196576

http://www.w3.org/2001/XMLSchema#string

P698

23580070

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3646160

http://www.w3.org/2001/XMLSchema#string